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cense.Abstract Aim of the work: To evaluate the associations of serum 25 hydroxy (OH) vitamin D
[25(OH)D] levels with cardiovascular risk factors as well as disease activity in women with SLE.
Patients and methods: Fifty women with SLE as well as 30 controls were included in our study.
Data collected included, demographics, SLE activity and damage assessments, cardiovascular risk
factors, medications and laboratory assessment of inﬂammatory markers and 25(OH)D levels. Step-
wise logistic regression analysis were used to estimate the association of 25(OH)D levels with car-
diovascular risk factors.
Results: A signiﬁcant lower 25(OH)D levels was found in SLE patients compared to controls
(P< 0.001). A positive correlation was found between 25(OH)D and diastolic blood pressure,
fasting blood sugar, cholesterol, triglycerides, LDL, BMI, as well as proteinuria and C3 levels. Fur-
thermore, a signiﬁcant positive correlation was found between 25(OH)D and the RT carotid artery0540534133.
.com (Y. Ezzat).
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196 Y. Ezzat et al.stenosis and RT carotid artery plaque and the intima media thickness of both left and right carotid
arteries. Lower 25(OH)D levels were also signiﬁcantly associated with higher SLE disease activity
and damage scores and steroid cumulative dose. Stepwise logistic regression analysis showed that
higher BMI, diastolic blood pressure, cholesterol, triglycerides, LDL and diabetes mellitus act as
predictors of lower 25(OH)D levels.
Conclusion: Our study found an association between lower 25(OH)D levels and increased
cardiovascular disease (CVD) risk factors, as well as increased SLE disease activity and damage
indices. Future studies are needed to determine relation of 25(OH)D and cardiovascular risk factors
in patients with lupus.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Several studies have suggested that 25-hydroxy vitamin
25(OH)D deﬁciency is an unrecognized contributor to the
development of cardiovascular disease (CVD), cancer, and
mortality. 1,25-Dihydroxy vitamin D affects the renin-angio-
tensin system [1], is associated with cardiac myocyte hyper-
trophy and has anti-inﬂammatory effects all of which may
inﬂuence CVD risk [2]. Data from the third National Health
and Nutrition Examination Survey (NHANES III) [3] found
that adults with 25(OH)D levels <20 ng/ml compared with
those with 25(OH)D levels P30 ng/ml had an increased
frequency of CVD, including coronary heart disease, heart
failure, stroke, and peripheral arterial disease.
A leading cause of morbidity and mortality in women with
SLE, including those who are premenopausal, is CVD [4] pa-
tients with lupus have an increased incidence of myocardial
infarction up to 5 times that of the general population, with
an age speciﬁc incidence in young women up to 50 times higher
[5]. Evidence has been shown that like diabetes mellitus (DM),
SLE itself is an independent risk factor for the development of
atherosclerosis [6].
The identiﬁcation of vitamin D receptor (VDR) in the cells
involved in immune response and the discovery that activated
dendritic cells produce vitamin D hormone suggested that vita-
min D could exert immunoregulatory effects [7]. Vitamin D
receptor is amember of the nuclear hormone receptor superfam-
ily and has been identiﬁed in mononuclear cells, dendritic cells,
antigen-presenting cells aswell as activatedT-B lymphocytes [8].
The effects of 1,25(OH)2D3 on the acquired, antigen-speciﬁc
immune response is inhibition of both TH1and TH2 cell cyto-
kine production, including IL-4, IL-6 [9,10], in addition vitamin
D has been studied as a modiﬁable environmental factor [11] in
autoimmune disease animal models, including SLE [12], exper-
imental autoimmune encephalomyelitis [13], rheumatoid arthri-
tis [14], type I DM [15] and inﬂammatory bowel disease [16].
SLE is the proto typical autoimmune disease and patients with
SLE are known to have lower levels of 25(OH)D with measure-
ments620 ng/ml [4] and in some cases, critically low at<10 ng/
ml [17]. Lower levels of vitamin D have been shown to correlate
with increased SLE disease activity [18] and studies using animal
models of SLE demonstrated the attenuation of some manifes-
tations with increasing vitamin D intake [3,12]. Our goal was to
detect the association between 25-hydroxy vitamin D and car-
diovascular risk factors in systemic lupus erythematosus pa-
tients and whether vitamin D levels are correlated with disease
activity parameters.2. Patients and methods
2.1. Study population
The study included 50 Egyptian SLE female patients with a
mean age of 29.38 ± 9.2 years, fulﬁlling the 1982 revised crite-
ria of the American Rheumatism Association for the classiﬁca-
tion of SLE [19], in addition to 30 healthy controls matched for
age and sex with a mean age of 30.4 ± 7.1 years. All 50 pa-
tients and controls were premenopausal and were subjected
to same sunlight exposure and clothing conditions. Three of
the 50 SLE patients had history of cardiovascular accidents
in the form of stroke which occurred in two patients and one
patient developed myocardial infarction. All subjects were
informed about the aim of the study and gave their consent.
Patients were collected from the Rheumatology and Rehabili-
tation Department, Cairo and Fayoum University Hospitals.
2.2. Laboratory testing
Blood was drawn at the time of the study for analyses which
included the following: antiphospholipid antibodies (aPL)
(positive if IgG or IgM ACL was >40 IU/ml or if the lupus
anticoagulants (‘‘LAC’’) was present. Antinuclear antibody
testing (ANA), antiDNA using indirect immunoﬂuorescence,
C-reactive protein (CRP), serum complement (C3 and C4) lev-
els by nephelometry and glomerular ﬁltration rate were done
to all patients. A complete blood picture, lipid proﬁle, serum
creatinine, liver function tests and electrolyte levels were tested
for all enrolled cases.
25(OH)D levels was measured in the Department of Chem-
ical Pathology, Cairo University Hospital by the 25(OH)D 125I
radioimmunoassay kit (Diasorin). The intra-assay coefﬁcient
of variation was 9.4%. Samples were measured in duplicate
and the average value was reported. We deﬁned vitamin D
deﬁciency as <25 nmol/l while vitamin D insufﬁciency was
between 25 and 75 nmol/l.
2.3. Traditional CVD risk factors
Information was obtained on age, smoking, diabetes, current
estrogen use, current aspirin use, menopause status and history
of cardiovascular disease (myocardial infarction, stroke, angi-
na, transient ischemic attacks TIAs).
Systolic and diastolic blood pressure were determined using
an average of 2 consecutive sittings 5 min apart. Blood
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ﬁned as an average systolic blood pressure P140 mmHg, an
average diastolic blood pressure P90 mmHg, or the use of
antihypertensive agents, in addition body mass index (BMI)
was calculated as weight in kilograms divided by height in me-
ters squared (kg/m2) [20].
2.4. SLE related factors
Validated measures of lupus disease activity (SLEDAI) [21]
and disease damage SLE international collaborating clinics
(SLICC) were completed. Renal disease was considered if there
is >0.5 g/day or 3+ proteinuria and or the presence of cellular
casts or had a renal biopsy sample with evidence of world
health organization class IIb, III, IV, or V lupus nephritis
[22]. History of steroid treatment was taken (current use and
duration of treatment) as well as current use of hydroxychloro-
quine and immunosuppressant (including cyclophosphamide,
azathioprine, methotrexate, mycophenolate mofetil and
cyclosporine).
2.5. Ultrasonographic studies
All ultrasonographic studies were performed on the day of the
study by an experienced radiologist and cardiologist.
Subclinical CVD was measured in the carotid arteries using
carotid artery B-mode US. Carotid plaque was deﬁned as a
distinct area protruding into the vessel lumen that was at least
50% thicker than the surrounding areas. The outcome mea-
sure used for analyses was the presence or absence of plaque
(plaqueP 1 versus plaque = 0).
The color Doppler map in the longitudinal and axial planes
was used to identify the sites of luminal stenosis, atheromatous
plaques or focal haemodynamically signiﬁcant stenotic areas.
Intima media thickness (IMT) was measured using specialized
reading soft wear across 1 cm segments of both the RT and LT
sides of the near and far walls of the distal common carotid
artery and the far wall of the bulb and internal carotid artery.
The mean of the average IMT reading across both sites was
used for analysis.
Statistics: Statistical analysis, Statistical Package for Social
Science program, version 15, was used for analysis of data.
Data was presented as number (percent) and mean ± SD.
Mann–Whitney test was used for the analysis of two quantita-
tive data. Spearman correlation was used for detection of the
relation between two variables. P value was considered signif-
icant if <0.05. Stepwise logistic regression analysis was per-
formed; to estimate the association between 25(OH)D levels
with cardiovascular risk factors. P< 0.05 was considered sta-
tistically signiﬁcant.
3. Results
3.1. Characteristics of the included patients
Fifty patients with SLE were examined during this study, with
a mean age of 29.3 ± 9.2 years and mean disease duration of
5.43 ± 4.56 years as well as 30 controls matched for age and
sex. Out of the 50 SLE patients 18 patients had nephritis
(36%) at some time during their disease course, and 12 patients
reported they were current smokers (24%).Self reported cardiovascular risk factors included 15 pa-
tients with hypertension (30%), 4 patients with diabetes melli-
tus (8%), 19 patients with hypercholesterolemia (38%) and 3
patients with history of cardiovascular disease (6%). In addi-
tion 9 subjects were found positive for anticardiolipin antibod-
ies (ACL) IgG IgM (18%) and 7 study subjects were found to
have positive lupus anticoagulants (14%). All patients were
taking steroids (dose ranged from 15 to 50 mg/day), 45
patients on hydroxychloroquine (dose ranged from 200 to
400 mg/day), 25 patients on azathioprine (dose ranged from
100 to 150 mg/day) and 15 patients were receiving monthly
cyclophosphamide pulse therapy depending on extent of renal
lesion (dose ranged from 700 to 1000 mg). Radiological read-
ings of the SLE patients found 5 patients with RT carotid ar-
tery stenosis, 4 patients with LT carotid artery stenosis, 4
patients with RT carotid plaque and 2 patients with LT carotid
plaque. Patient descriptive data is shown in Table 1.
3.2. Prevalence of vitamin D deﬁciency
The mean level of 25(OH)D was 26.3 ± 5.58 nmol/l in the
SLE group while it was 30.7 ± 4.68 nmol/l in the control
group. Out of the 50 SLE patients recorded in our study, there
were 18 patients (36%) who were vitamin D deﬁcient
(<25 nmol/l) and 32 patients (64%) who were vitamin D
insufﬁcient (25–75 nmol/l). Our control group included 17
vitamin D insufﬁcient individuals (57%), 5 vitamin D deﬁcient
individuals (16.7%) and 8 with normal vitamin D levels. There
was a positive signiﬁcant difference between 25(OH)D levels in
SLE patients and controls (P< 0.001) data is shown in Table
2 and graphically presented in Fig. 1.
3.3. 25-Hydroxy vitamin D levels and cardiovascular risk factors
No relationship was found between 25(OH)D and both lupus
anticoagulants and anticardiolipin antibodies IgG, IgM
(P= 0.087 and 0.197, respectively). In addition no correlation
was found between 25(OH)D and cerebrovascular events or
smoking (P= 0.125 and 0.127, respectively).
On the other hand a signiﬁcant positive correlation was
found between 25(OH)D diastolic blood pressure and fasting
blood sugar (P= 0.011 and <0.001, respectively). While there
was a signiﬁcant negative correlation between BMI and
25(OH)D (P< 0.001). As regarding the correlation between
the lipid proﬁle in the SLE patients and 25(OH)D levels, a
positive signiﬁcant correlation was found with cholesterol, tri-
glycerides and LDL levels (P< 0.001, <0.001 and 0.005,
respectively).
Furthermore, a signiﬁcant positive correlation was found
between 25(OH)D and the RT carotid artery stenosis and
RT carotid artery plaque (P= 0.004 and 0.013, respectively),
in addition a positive correlation was found between 25(OH)D
and the intima media thickness of both left and right carotid
arteries (P= 0.002 and 0.010, respectively) (Table 3).
3.4. 25-Hydroxy vitamin D levels and SLE related factors
Our study showed a signiﬁcant positive correlation between
25(OH)D and SLE SLEDAI and SLICC scores (P= 0.006
and 0.05, respectively).
Table 1 descriptive data of the studied SLE patients.
Characteristics Value n (%), mean ± SD
Duration (years) 5.43 ± 4.56
Age mean 29.38 ± 9.2
Nephritis 26/50 (52%)
Serositis 10/50 (20%)
BMI (kg/m2) 25.8 ± 6.4
SLEDAI score 17.5 ± 8.3
SLICC 0.56 ± 0.9
Cardiovascular risk factor
Smokers 12/50 (24%)
Hypertension 15/50 (30%)
SBP (mmHg) 132.2 ± 14.99
DBP (mmHg) 87.4 ± 9.5
Hypercholesterolemia 19/50 (38%)
CVS 3/50 (6%)
RT CA stenosis 5/50 (10%)
LT CA stenosis 4/50 (8%)
RT CA plaque 4/50 (8%)
LT CA plaque 2/50 (4%)
Diabetes mellitus 7/50 (14%)
Laboratory data
25(OH)D (nmol/l) 31.7 ± 12.5
FBS (mg/dl) 92.9 ± 16.5
Cholesterol (mg/dl) 194.4 ± 63.6
Triglycerides (mg/dl) 188.2 ± 65.6
HDL (mg/dl) 61.2 ± 15.0
LDL (mg/dl) 137.6 ± 37.1
ACL positive 9/50 (18%)
LAC positive 7/50 (14%)
CRP (mg/dl) 4.2 ± 10.2
Creatinine (mg/dl) 1.0 ± 1.4
Glomerular ﬁltration rate (ml/min) 68.2 ± 19.2
C3 (mg/dl) 95 ± 32
C4 (mg/dl) 19.4 ± 8.9
Current medications
Steroid dose (mg/day) 25.0 ± 8.03
Steroid duration/year 3.86 ± 2.57
HQN dose (mg/day) 380.0 ± 60.6
HQN duration/year 3.67 ± 2.4
Imuran dose (mg/day) 111.0 ± 40.7
Imuran duration (years) 2.47 ± 1.8
CYC cumulative dose (g) 3.79 ± 3.8
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic
blood pressure; CVS: coronoray vascular disease; CA: carotid
artery; HDL: high density lipoprotein; LDL: low density lipopro-
tein; ACL: anticardiolpin antibodies; LAC: lupus anticoagulants.
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25(OH)D levels, proteinuria and C3 levels (P= 0.006 and
<0.00,1 respectively). As regards medications given, there
was a signiﬁcant negative correlation between the durationTable 2 25(OH)D status in SLE and control patients.
25(OH)D levels SLE patients (n= 50)
N (%) Mean ± S
Deﬁciency (<25 nmol/l) 18 (36%) 19.1 ± 9.5
Insuﬃciency (25–75 nmol/l) 32 (64%) 28.1 ± 2.7
Overall 25(OH)D levels 50 (100%) 26.3 ± 5.5of steroid use and its cumulative dose and 25(OH)D levels
(P= 0.008 and 0.02, respectively), while there was no correla-
tion between hydroxychloroquine or immunosuppressant and
the levels of 25(OH)D.
3.5. Predictors of 25(OH)D levels
The following variables were independent predictors of lower
25(OH)D levels using stepwise logistic regression analysis,
higher BMI (OR 0.83; 95% CI 0.78, 0.88), diastolic blood pres-
sure (OR 0.70; 95% CI 0.58, 0.84), cholesterol (OR 0.70; 95%
CI 0.63, 0.78), triglycerides (OR 0.66; 95% CI 0.55, 0.79), LDL
(OR 0.62; 95% CI 0.46, 0.74) and DM (OR 0.59; 95% CI 0.47,
0.76) (Table 4).
4. Discussion
In SLE, many causes of vitamin D deﬁciency exist [23] with
some of the most common causes being reduced skin synthesis
and absorption of vitamin D due to sunscreen use, darker skin
pigment, aging, season, latitude, and time of day [23,24]. These
causes are particularly relevant in patients with lupus because
of disease related photosensitivity and increased use of
sunscreen.
Other lupus related factors that may contribute to vitamin
D deﬁciency include renal disease [25], use of steroids that are
thought to alter the metabolism of vitamin D [26] and hydrox-
ylchloroquine [27].
Our ﬁndings in this study noting an association between
CVD risk factors and low vitamin D levels are consistent with
those reported in the general population [19].
Data from the third National Health and Nutrition Exam-
ination Survey (NHANES III) [19], showed that patients
within the lowest vitamin D level (<20 ng/ml), had a signiﬁ-
cantly increased prevalence of selected CVD risk factors
(including a history of diabetes and elevated blood pressure,
fasting blood glucose, BMI and triglycerides) when compared
with the highest level (>37 ng/ml).
In addition several studies have shown relationship between
25(OH)D level, CVD events, and CVD mortality, even after
adjusting for traditional CVD risk factors [28]. Within the
SLE population, no studies have documented an association
between vitamin D levels and CVD risk factors or outcomes
except that of Wu et al. [29] who found that lower 25(OH)D
levels to be associated with several cardiovascular risk factors
in the univariate model.
On the opposite of our study, Hsia et al. [30] found that
calcium and vitamin D supplementation in healthy postmeno-
pausal women aging 50–70 years, neither increased nor
decreased the risk of myocardial infarction, coronary heart
disease or death over a period of 7 years.Control (n= 30) P-value
D N (%) Mean ± SD
5 (16.7%) 22.9 ± 6.7 <0.001
17 (57%) 35.6 ± 5.5 0.010
8 22 (73%) 30.7 ± 4.68 <0.001
Table 3 Cardiovascular risk factors in 25(OH)D deﬁcient and insufﬁcient patients.
25(OH)D total levels (N= 50) 25(OH)D deﬁciency (N= 18) 25(OH)D insuﬃciency (N= 32) P-value
DBP (mean ± SD) 87.4 ± 9.5 88.6 ± 10.4 80 ± 4.5 0.011
FBS (mean ± SD) 92.9 ± 16.5 102.3 ± 20.9 87.6 ± 10.7 <0.001
BMI (mean ± SD) 25.8 ± 6.4 30.1 ± 6.2 23.4 ± 5.2 <0.001
SLEDAI score (mean ± SD) 17.5 ± 8.3 22.9 ± 10 14.5 ± 5.5 0.006
SLICC score (mean ± SD) 0.56 ± 0.9 1.0 ± 1.2 0.31 ± 0.6 0.003
Cholesterol (mean ± SD) 194.4 ± 63.6 217.5 ± 60.2 174.4 ± 65.7 <0.001
TG (mean ± SD) 188.2 ± 65.6 199.3 + 61.1 164.4 + 52.9 <0.001
HDL (mean ± SD) 61.2 ± 15.0 52.31 ± 15.9 63.0 ± 13.4 0.074
LDL (mean ± SD) 142.2 ± 33.6 157.7 ± 32. 126.4 ± 35.3 0.005
ACL IgG IgM +ve 9 (18%) 1 (5.6%) 8 (25%) 0.087
LAC +ve 7 (14%) 1 (5.6%) 6 (18.8%) 0.197
CVS, n (%) 3 (6%) 2 (11.1%) 1 0.133
Subclinical markers of CVD
RT CA IMT (mean ± SD) 3.4 ± 0.9 4.1 ± 1.5 3.0 ± 0.8 0.002
LT CA IMT (mean ± SD) 3.8 ± 1.3 4.2 ± 1.9 3.1 ± 1 0.010
RT CA stenosis, n (%) 5 (10%) 5 (27.8%) 0 0.006
LT CA stenosis, n (%) 4 (8%) 3 (16.7%) 1 (3.1%) 0.127
RT CA plaque, n (%) 4 (8%) 4 (22.2%) 0 0.013
LT CA plaque, n (%) 2 (4%) 2 (11.1) 0 0.125
Figure 1 25(OH)D deﬁciency and insufﬁciency status in SLE and control patients.
Table 4 Predictive factors of low 25(OH)D.
Signiﬁcant predictors OR (95% CI) P-value
BMI 0.83 (0.78, 0.88) <0.001
DBP 0.70 (0.58, 0.84) <0.001
Cholesterol 0.70 (0.63, 0.78) <0.001
Triglyceride 0.66 (0.55, 0.79) <0.001
LDL 0.62 (0.46, 1.12) 0.002
DM 0.59 (0.47, 0.76) 0.003
BMI: bone mineral density; DBP: diastolic blood pressure; LDL:
low density lipoprotein; DM: diabetes mellitus.
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were associated with higher BMI, diastolic blood pressure, LDLcholesterol, triglycerides and self reported hypertension and
DM using stepwise regression analysis.
It is not clear why BMI abrogates most of the relationships
between CVD risk factors and 25(OH)D. One explanation
may be that BMI acts as a mediator between the two by
contributing to the inﬂammatory load of women with SLE.
No signiﬁcant relationship was found between cerebrovascular
events and 25(OH)D levels in this study, but the number of
events was too few to consider this an accurate assessment.
We did however, look at the relationship between 25(OH)D lev-
els andmarkers of subclinical atherosclerosis (plaque and IMT).
This is important because the presence or extent of carotid pla-
que, increased IMT have been found to predict risk of cardio-
200 Y. Ezzat et al.vascular events includingmyocardial infarction [27] similarly in-
creased IMTand carotid plaques have been found to predict risk
of angina and stroke in the general population [31].
In agreement with this data, our study found a signiﬁcant
positive correlation between 25(OH)D and the RT carotid
artery stenosis and RT carotid artery plaque, in addition a
positive correlation was found between 25(OH)D and the inti-
ma media thickness of both left and right carotid arteries.
We also found that lower 25(OH)D levels were associated
with increased lupus disease activity and damage indices which
is consistent with most other studies [12]. This is important
because vitamin D have a beneﬁcial role in preventing or atten-
uating some manifestations of SLE. In fact, treatment with
various levels of 1,25(OH)2D3 in animal models of lupus
reduced dermatologic lesions of lupus such as alopecia, in
addition to proteinuria and serum anti-ds-DNA antibodies
[12]. On the other hand Ruiz-Irastorza et al. [6] stated that
treatment with vitamin D3 reduces fatigue in SLE patients as
measured by 0–10 VAS but does not affect SLE activity or
damage index.
Our study concluded a positive signiﬁcant correlation
between 25(OH)D and cholesterol, triglycerides and LDL lev-
els which shows that cholesterol and triglycerides acted as a
predictive factors for vitamin D deﬁciency which further
emphasizes that lipid proﬁle is considered a major CVD risk
factor in women with SLE.
Also our study showed a positive correlation between
25(OH)D levels and proteinuria and C3 levels, this may be
an important factor as 1-hydroxylation is essential to make
25-OH vitamin D active which can be disrupted in signiﬁcant
renal disease, we did not ﬁnd a signiﬁcant relationship between
the glomerular ﬁltration rate (GFR) and the level of 25(OH)D
which may be related to the limited number of patients.
As regards the medications used, our study showed a signif-
icant negative correlation between 25(OH)D and the duration
of steroid use and its cumulative dose while there was no corre-
lation with the other medications given including hydroxychlo-
roquine and other immunosuppressants. Chronic steroid use
may result in altered metabolism of vitamin D, although there
is contradictory evidence [26]. Dihydroxy-vitamin D3 has been
demonstrated to be reduced in corticosteroid-treated patients
with a variety of collagen vascular diseases and rheumatoid
arthritis [32]. In rat models, steroids have been demonstrated
to alter vitamin D metabolism, leading to the formation of
more polar, biologically inactive metabolites that result in de-
creased intestinal calcium absorption [33]. The data on whether
corticosteroids are pro or antiatherogenic are controversial, but
some suggest that the progression of subclinical atherosclerosis
based on serial carotid ultrasound correlates with lower mean
dose of steroids and less aggressive immunosuppressive therapy
[34]. However, corticosteroid use has also been associated with
higher IMT and frequency of carotid plaque in patients with
rheumatoid arthritis, and it is thought to increase the catabo-
lism of vitamin D, thus lowering serum levels [35].
The data on the effects of hydroxychloroquine on vitamin
D are also controversial [36]. Hydroxychloroquine is suspected
to inhibit the conversion of 25(OH)D to its more biologically
active form, 1,25-dihydroxy vitamin D, but also had been
found to protect against vitamin D deﬁciency [37]. In terms
of cardiovascular effects, hydroxychloroquine has been shown
to be protective against thrombosis and cardiac disease [35].A limitation of our study was the small number of patients,
which needs to be further evaluated in large cohort of patients
to determine the protective effect of adequate vitamin D levels
on the development of SLE.
In conclusion, our study found an association between lower
25(OH)D levels and increased CVD risk factors, as well as in-
creased SLE disease activity and damage indices, also with the
presence of proteinuria, low complement levels and steroid use.
The physiologic and clinical effects of using vitamin D to
modulate SLE disease activity and damage are not known
nowadays, and there are currently no prospective studies look-
ing at the effects of vitamin D supplementations in SLE. How-
ever, future studies are needed to determine whether vitamin D
levels can predict the progression of subclinical atherosclerosis
as measured by imaging markers as well as cardiovascular
events in patients with lupus.Conﬂict of Interest
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